Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (08-03). Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

JAN 20 2004 JC#6
PATENT & TRADEMARK OFFICE

Sheet 1 of 6

COMPLETE IF KNOWN	
Application Number	10/688,691
Filing Date	October 17, 2003
First Named Inventor	Steven S. Carroll, et al.
Group Art Unit	1623
Examiner Name	
Attorney Docket Number	20717YCA

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	1	3,480,613		Walton	11/25/1969
	2	6,348,587		Schinazi et al.	02/19/2002
	3	US 2002/0019363 A1		Ismaili et al.	02/14/2002
	4	US 2002/0198171 A1		Schinazi et al.	12/26/2002
	5	US 2003/0060400 A1		LaColla et al.	03/27/2003
	6	US 2003/0050229 A1		Sommadossi et al.	03/13/2003
	7	US 2002/0055483 A1		Watanabe et al.	05/09/2002

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	8	PCT	WO 01/90121		NOVIRIO PHARMACEUTICALS LIMITED	11/29/2001
	9	PCT	WO 01/92282		NOVIRIO PHARMACEUTICALS LIMITED	12/06/2001
	10	PCT	WO 93/18051		JAPAN TOBACCO INC.	09/16/1993
	11	PCT	WO 01/79246		PHARMASSET, LTD.	10/25/2001
	12	PCT	WO 99/43691		EMORY UNIVERSITY & THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.	09/02/1999
	13	PCT	WO 01/60315		BIOCHEM PHARMA INC.	08/23/2001
	14	PCT	WO 01/32153		BIOCHEM PHARMA INC.	05/10/2001
	15	PCT	WO 02/18404		F. HOFFMANN-LA ROCHE AG	03/07/2002
	16	GB	1209 654		MERCK & CO., INC.	10/21/1970
	17	FR	1.581.628		MERCK & CO., INC.	09/19/1969

Examiner Signature	L. E. Crane	Date Considered	01/29/2006

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

COPY For [] File [X] Applicant

Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (08-03), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

JAN 20 2004 JC
PATENT & TRADEMARK OFFICE

Sheet	2	of	6

COMPLETE IF KNOWN	
Application Number	10/688,691
Filing Date	October 17, 2003
First Named Inventor	Steven S. Carroll, et al.
Group Art Unit	1623
Examiner Name	
Attorney Docket Number	20717YCA

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	18	PCT	WO 02/048165 A2		PHARMASSET LTD.	06/20/2002
	19	PCT	WO 02/048165 A3		PHARMASSET LTD.	06/20/2002
	20	PCT	WO 02/069903 A2		BIOCRYST PHARMACEUTICALS, INC.	09/12/2002
	21	PCT	WO 02/069903 A3		BIOCRYST PHARMACEUTICALS, INC.	09/12/2002
	22	PCT	WO 02/100354 A2		RIBAPHARM INC.	12/19/2002
	23	PCT	WO 02/100354 A3		RIBAPHARM INC.	12/19/2002
	24	PCT	WO 02/100415 A2		F. HOFFMAN-LA ROCHE AG	12/19/2002
	25	PCT	WO 03/000200 A2		PHARMASSET LTD.	01/03/2003
	26	PCT	WO 03/000713 A1		GLAXO GROUP LIMITED	01/03/2003
	27	PCT	WO 03/015798 A1		TOYAMA CHEMICAL CO.,LTD.	02/27/2003

Examiner Signature	L. E. Crama	Date Considered	01/29/2006

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

10/688,691 - PTO-1449 #1 COPY FOR [] File [X] Applicant

Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (08-03), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

JAN 20 2006 PATENT & TRADEMARK OFFICE

Sheet 3 of 6

COMPLETE IF KNOWN	
Application Number	10/688,691
Filing Date	October 17, 2003
First Named Inventor	Steven S. Carroll, et al.
Group Art Unit	1623
Examiner Name	
Attorney Docket Number	20717YCA

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	28	PCT	WO 03/062255		RIBAPHARM INC.	07/31/2003
	29	PCT	WO 03/051899		RIBAPHARM INC.	06/26/2003
	30	PCT	WO 03/051898		RIBAPHARM INC.	06/26/2003
	31	PCT	WO 03/051897		RIBAPHARM INC.	06/26/2003
	32	PCT	WO 03/051896		RIBAPHARM INC.	06/26/2003
	33	PCT	WO 03/051881		RIBAPHARM INC.	06/26/2003
	34	PCT	WO 03/026589 A2		IDENIX (CAYMAN) LIMITED	04/03/2003
	35	PCT	WO 03/026675 A1		IDENIX (CAYMAN) LIMITED	04/03/2003
	36	PCT	WO 02/094289 A1		F. HOFFMANN-LA ROCHE AG	11/28/2002
	37	PCT	WO 03/093290 A2		GENELABS TECHNOLOGIES, INC.	11/13/2003

Examiner Signature	L. E. Crabe	Date Considered	01/29/2006

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (08-03), Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

JAN 20 2004 JC6 U.S. PATENT & TRADEMARK OFFICE

Sheet 4 of 6

COMPLETE IF KNOWN	
Application Number	10/688,691
Filing Date	October 17, 2003
First Named Inventor	Steven S. Carroll, et al.
Group Art Unit	1623
Examiner Name	
Attorney Docket Number	20717YCA

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Office	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
/LE/	38	PCT	WO 02/32920 A2	A2	PHARMASSET LIMITED	04/25/2002

Examiner Signature	L. E. Crane /LE Crane/	Date Considered	01/29/2006

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (08-03). Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

JAN 20 2004
PATENT & TRADEMARK OFFICE

Sheet 5 of 6

Application Number	10/688,691
Filing Date	October 17, 2003
First Named Inventor	Steven S. Carroll, et al.
Group Art Unit	1623
Examiner Name	
Attorney Docket Number	20717YCA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
	39	Walton, E. et al., "Branched-Chain Sugar Nucleosides. V. Synthesis and Antiviral Properties of Several Branched-Chain Sugar Nucleosides", J. Med. Chem., Vol. 12, pp. 306-309 (1969)
	40	Matsuda, A. et al., "Radical Deoxygenation of Tert-Alcohols In 2'-Branched-Chain Sugar Pyrimidine Nucleosides: Synthesis and Antileukemic Activity of 2' -Deoxy-2' (S)-Methylcytidine", Chem. Pharm. Bull., Vol. 35, pp. 3967-3970 (1987)
	41	Matsuda, A. et al., "Alkyl Addition Reaction of Pyrimidine 2'-Ketonucleosides: Synthesis of 2' -Branched-Chain Sugar Pyrimidine Nucleosides (Nucleosides and Nucleotides. LXXXI), Chem. Pharm. Bull., Vol. 36, pp. 945-953 (1988)
	42	Murai, Y. et al., "A Synthesis and an X-Ray Analysis of 2'-C-, 3'-C- and 5'-C-Methylsangivamycins", Heterocycles, Vol. 33, pp. 391-404 (1992)
	43	Limori, T. et al., "2'-C-, 3'-C- and 5'-C-Methylsangivamycins: Conformational Lock with the Methyl Group", Tetrahedron Letters, Vol. 3, No. 49, pp. 7273-7276 (1991)
	44	Wolfe, M. et al., "A Consise Synthesis of 2'-C-Methylribonucleosides", Tetrahedron Letters, Vol. 36, No. 42, pp. 7611-7614 (1995)
	45	Harry-O'kuru, R. et al., "A Short, Flexible Route toward 2'-C-Branched Ribonucleosides", J. Org. Chem., Vol. 62, pp. 1754-1759 (1997)
	46	Gallo, M. et al., "Synthesis of 2'-Modified Nucleotides", Molecules, Vol. 5, pp. 727-729 (2000)
	47	Beigelman, L. et al., "New Synthesis of 2'-C-Methylnucleosides Starting From D-Glucose and D-Ribose", Carbohydrate Research, Vol. 166, pp. 219-232 (1987)
	48	Anzai, K. et al, "A New Antibiotic, Tubercidin", The Journal of Antibiotics., Vol. X, No. 5, pp. 201-205 (1957)
	49	Tolman, R. et al., "Pyrrolopyrimidine Nucleosides. III. The Total Synthesis of Toyocamycin, Sangivamycin, Tubercidin, and Related Derivatives", Journal of the American Chemical Society, Vol. 91, No. 8, pp. 2102-2108 (1969)
	50	Tolman, R. et al., "Pyrrolo[2,3-d]pyrimidine Nucleoside Antibiotics. Total Synthesis and Structure of Toyacamycin, Unamycin B, Vengicide, Antibiotic E-212, and Sangivamycin (BA-90212)", Journal of the American Chemical Society, Vol. 90, No. 2, pp. 24-526 (1968)
	51	Siddiqi, S. et al., "Search for New Purine- and Ribose-Modified Adenosine Analogues as Selective Agonists and Antagonists at Adenosine Receptors", J. Med. Chem., Vol. 38, pp. 1174-1188 (1995)
	52	Franchetti, P. et al., "2'-C-Methyl Analogues of Selective Adenosine Receptor Agonists: Synthesis and Binding Studies", J. Med. Chem., Vol. 41, pp. 1708-1715 (1988)
	53	Kalinichenko, E. et al, "Substrate Specificity of Adenosine Deminase. Role of Methyl Groups at the 2'-, 3'-, and 5'-Carbon Atoms of Adenosine", Bioorganicheskaya Khimiya, Vol. 14, No. 9, pp. 1157-1161 (1988)

Examiner Signature	L. E. Crane	Date Considered	01/29/2006

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form "IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003

Approved for use through 7/31/2006. OMB 0651-0031
SUBSTITUTE for PTO/SB/08A (08-03). Information Disclosure Statement by Applicant
Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

O I P E
JAN 2 0 2004
PATENT & TRADEMARK OFFICE
JC#0

Sheet	6	of	6

COMPLETE IF KNOWN	
Application Number	10/688,691
Filing Date	October 17, 2003
First Named Inventor	Steven S. Carroll, et al.
Group Art Unit	1623
Examiner Name	
Attorney Docket Number	20717YCA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
LEC	54	Wolf, et al., "New 2'-C-Branched-Chain Sugar Nucleoside Analogs with Potential Antiviral or Antitumor Activity", Synthesis, pp. 773-778 (August 1992)

Examiner Signature	L. E. Crane	Date Considered	01/29/2006

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form " IDS Form" (IDS Folder), Merck & Co., Inc., 09/05/2003